Kinnate jumps onto the biotech stage with $74.5M and a fledgling cancer drug pipeline
Cancer continues to be the disease category of choice among a large swath of biotech VCs.
San Diego-based Kinnate has jumped out from the shadows …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
